尼可地尔联合阿托伐他汀对冠状动脉支架植入患者的影响

Effect of Nicorandil Combined with Atorvastatin on Patients Undergoing Coronary Stenting

目的探究尼可地尔联合阿托伐他汀在冠状动脉支架植入患者中的应用效果。方法选取2022年10月-2023年9月我院收治的66例冠状动脉支架植入患者,以随机数字表法将其分为对照组和观察组,每组各33例。对照组实施阿托伐他汀治疗,观察组实施尼可地尔联合阿托伐他汀治疗。对两组患者治疗前后的心电图参数、心肌酶水平以及血小板活化分子进行比较。结果治疗前两组患者心电图参数、心肌酶水平、血小板活化分子比较均无统计学意义(P>0.05),治疗后QTc间期及QRS时限等心电图参数、AST、CK以及LDH等心肌酶水平、PAR1、CCR2以及HSP27血小板活化分子均显著低于对照组(P<0.05)。结论冠状动脉支架植入患者应用尼可地尔联合阿托伐他汀治疗,可显著改善患者心电图参数,减轻心肌损伤,降低血小板活化。

Objective:To explore the effect of nicorandil combined with atorvastatin in patients undergoing coronary stenting.Methods:A total of 66 patients with coronary stents admitted to our hospital from October 2022 to September 2023 were selected,and were randomly divided into the control group and the observation group,with 33 cases in each group.The control group was treated with atorvastatin,and the observation group was treated with nicorandil combined with atorvastatin.Electrocardiogram parameters,cardiac enzyme levels and platelet activation molecules before and after treatment were compared between the two groups.Results:Before treatment,there was no significant difference in ECG parameters,cardiac enzyme levels and platelet activation molecules between the two groups(P>0.05).After treatment,ECG parameters such as QTc interval and QRS duration,cardiac enzyme levels such as AST,CK and LDH,PAR1,CCR2 and HSP27 platelet activation molecules were significantly lower than those of the control group(P<0.05).Conclusion:Nicorandil combined with atorvastatin in patients undergoing coronary stenting can significantly improve ECG parameters,alleviate myocardial injury,and reduce platelet activation.